Navigation Links
Anthera Pharmaceuticals Reports 2012 Third Quarter Financial Results And Provides Clinical Progress Update
Date:10/25/2012

HAYWARD, Calif., Oct. 24, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended September 30, 2012.

Financial Results and Corporate Update:

Total operating expenses for the third quarter ended September 30, 2012 were $12.0 million, as compared to $17.6 million for the second quarter ended June 30, 2012. The decrease in operating expenses for the period is related primarily to the reduced clinical activity following the completion and wind-down of activities on the PEARL-SC study.

Anthera ended the third quarter of 2012 with approximately $42.5 million in cash and cash equivalents and short-term investments. On July 24, 2012, the Company completed a public offering of shares of its common stock resulting in net proceeds of approximately $35.6 million from the sale of 37,950,000 shares, which includes 4,950,000 shares issued upon the exercise in full of the underwriters' over-allotment option.

Anthera will host a conference call at 1:00 p.m. Eastern Time tomorrow, October 25, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 44939072. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 44939072.  The audio replay will be available until November 1, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • Subsequent clinical results from the Phase 2b PEARL-SC study, which examined the therapeutic effect of blisibimod, indicate that in the predefined population of patients with clinically active disease (SELENA-SLEDAI* >/= 10) who were also taking corticosteroids, the SRI-8** treatment effects in the 200 mg
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Anthera to Report Second Quarter 2012 Financial Results
    2. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
    3. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
    4. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
    5. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
    6. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
    7. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
    8. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
    9. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
    10. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
    11. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... 2014 Hussey Copper , a leader ... antimicrobial copper, announces Gilmour Academy Ice Arena,s conversion of ... antimicrobial solid touch surface to help protect against bacteria.  ... surface that kills greater than 99.9% of MRSA, E-coli ... , Innovative ...
    (Date:9/17/2014)... FRANCISCO, Calif. , Sept. 17, 2014 ... a molecular diagnostics company pioneering the field of molecular ... to chief operating officer. Mr. Hall joined ... the company,s commercial entry into endocrinology. Since 2012, he ... as well as managed care and billing functions. As ...
    (Date:9/17/2014)... Beckman Coulter , a global leader ... renewed its agreement with Personify for an ... Personify will continue to streamline the Beckman Coulter talent ... including time-to-fill, time-to-source and a deep reduction to cost-per-hire. ... was based on the success of our partnership over ...
    (Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 ... to have one of its latch valves, V27200-818, operating ... scientific investigation of the planet Mercury. It is only ... has provided a vast amount of information and images ... valves utilize solenoids that also include permanent magnets to ...
    Breaking Biology Technology:Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3
    ... China, Dec. 15 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a leading,developer and distributor of ... medicines (TCM), nutritional and dietary supplements,medical devices ... from,the Guangdong Food & Drug Administration to ...
    ... to Support Phase 3 Combination Rule Trial for NDA ... Australia and BEDMINSTER, N.J., Dec. 15 QRxPharma Limited ... company focused on the development and commercialization of therapies ... today initiation of a comparative study to evaluate the ...
    ... Platform Brings System Flexibility and Efficiency to the Advanced ... Scanning Systems , , ... confocal microscope and software package available, Nikon Instruments, Inc.,s ... scanning systems with dedicated NIS-Elements C software brings biological ...
    Cached Biology Technology:China Medicine to Distribute Dental and Surgical Instruments 2China Medicine to Distribute Dental and Surgical Instruments 3QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 2QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 3Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 2Nikon Instruments A1 Confocal Laser Microscope Series With NIS-Elements C Software Delivers Fully Integrated Comprehensive Confocal Imaging Capabilities 3
    (Date:9/16/2014)... Health at the Mailman School of Public Health are ... and prenatal exposure to two phthalates used in a ... the journal Environmental Health Perspectives . , ... levels of the chemicals, butylbenzyl phthalate (BBzP) and di-n-butyl ... increase in risk of developing asthma between age 5 ...
    (Date:9/16/2014)... Ohio (September 17, 2014)The North American Menopause Society ... the comprehensive care of midlife womenon everything from ... "The North American Menopause Society Recommendations for Clinical ... in the Society,s journal Menopause . This ... for the care of midlife women freely available ...
    (Date:9/16/2014)... the "molecular brakes" that time the generation of important ... "hair cells" translate sound waves into electrical signals that ... sounds. If the arrangement of the cells is disordered, ... research will be published in The Journal of ... and Hey2 act as brakes to prevent hair cell ...
    Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
    ... Virginia Commonwealth University immunologists studying mast cells, known to ... have identified a hormone-like molecule that can kill these ... mice. , The findings move researchers another step ... and may help researchers develop new treatments for allergy ...
    ... day, tens of thousands of biologists around the globe ... online algorithm called BLAST ?typically submitting 200 to 400 ... matched against the billions of letters for known genes. ... or evolutionary relationships, scientists routinely use BLAST to churn ...
    ... captures pictures beneath the living brain's surfaceResearchers at Stanford ... that can capture micron-scale images from deep in the ... combines a pair of powerful optical and mechanical techniques ... the hand. The results appear in the September 1, ...
    Cached Biology News:VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease 2Drawing with DNA: 'Bioart' illuminates genomics 2Drawing with DNA: 'Bioart' illuminates genomics 3Microscopic brain imaging in the palm of your hand 2Microscopic brain imaging in the palm of your hand 3
    Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
    A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
    ... immunosorbent assay (ELISA) test kits are ... for the detection of drugs and/or their ... intended for forensic use only. It is ... by a quantitative method such as GC/MS. ...
    ... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
    Biology Products: